Low-dose naltrexone, or LDN, is an option that many patients with chronic pain and…

Summary

Low-dose naltrexone offers an approach for patients managing chronic pain and inflammatory conditions. In this overview, the medication is explained as a way to modulate immune activity and calm overactive pain signaling. It may be considered for complex conditions including fibromyalgia and mast cell activation syndrome, sometimes alongside disease-modifying antirheumatic drugs. Because response develops slowly, treatment relies on careful dose escalation over several weeks or months under medical guidance.

Conditions and treatments discussed

• Low-dose naltrexone. LDN may modulate immune activity and calm overactive pain signaling in chronic pain and inflammatory conditions.
• Fibromyalgia. Fibromyalgia is noted as a condition where LDN may be considered to help address overactive pain signaling.
• Mast cell activation syndrome. MCAS is described as an inflammatory condition where LDN may be used alongside other systemic therapies.
• Topical naltrexone. Topical formulations of naltrexone may be considered for inflammatory skin conditions such as psoriasis.

What this shows about Manhattan Pain Medicine

In this update, the practice emphasizes patient education by introducing low dose naltrexone as a potential therapy for chronic pain and systemic inflammation. The post explains how the medication modulates immune signaling and requires gradual dose titration over several weeks or months. It also highlights how this therapy can be combined with other treatments such as disease modifying antirheumatic drugs. The practice also describes establishing a complete diagnosis first as part of its general approach, identifying underlying pain mechanisms before initiating systemic therapies.